CN105311119A - Refined rhizoma corydalis decumbentis total alkaloid product, preparation method thereof, pharmaceutical composition and application of refined rhizoma corydalis decumbentis total alkaloid product and pharmaceutical composition - Google Patents
Refined rhizoma corydalis decumbentis total alkaloid product, preparation method thereof, pharmaceutical composition and application of refined rhizoma corydalis decumbentis total alkaloid product and pharmaceutical composition Download PDFInfo
- Publication number
- CN105311119A CN105311119A CN201410380316.8A CN201410380316A CN105311119A CN 105311119 A CN105311119 A CN 105311119A CN 201410380316 A CN201410380316 A CN 201410380316A CN 105311119 A CN105311119 A CN 105311119A
- Authority
- CN
- China
- Prior art keywords
- summer
- total
- refined
- total alkaloids
- free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 99
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 241000218176 Corydalis Species 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 47
- 239000000284 extract Substances 0.000 claims abstract description 15
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims abstract description 11
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 claims abstract description 11
- RLQYRXCUPVKSAW-UHFFFAOYSA-M 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;chloride Chemical compound [Cl-].COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=C1 RLQYRXCUPVKSAW-UHFFFAOYSA-M 0.000 claims abstract description 9
- 241000282339 Mustela Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 239000012528 membrane Substances 0.000 claims description 40
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 29
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 21
- 150000007529 inorganic bases Chemical class 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 238000000926 separation method Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- 239000003513 alkali Substances 0.000 claims description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 238000001728 nano-filtration Methods 0.000 claims description 6
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 230000005779 cell damage Effects 0.000 claims description 5
- 208000037887 cell injury Diseases 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 5
- 230000010410 reperfusion Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000011260 aqueous acid Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000008282 halocarbons Chemical class 0.000 claims description 4
- 239000012510 hollow fiber Substances 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 238000010979 pH adjustment Methods 0.000 claims description 4
- 238000001223 reverse osmosis Methods 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 3
- 150000008280 chlorinated hydrocarbons Chemical group 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000001471 micro-filtration Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 12
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 239000000463 material Substances 0.000 description 16
- 229910021529 ammonia Inorganic materials 0.000 description 10
- -1 preparation method Substances 0.000 description 7
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 6
- 230000003113 alkalizing effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000658 coextraction Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229940127240 opiate Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 4
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 3
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 244000283482 Alloteropsis cimicina Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- 241001537328 Corydalis decumbens Species 0.000 description 1
- 235000017898 Digitaria ciliaris Nutrition 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 230000004436 pseudomyopia Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了夏天无总生物碱精制物、制备方法、药物组合物及应用。本发明提供了夏天无总生物碱精制物,总生物碱精制物中各组分的重量百分比分别为:原阿片碱:15%~40%;延胡索乙素:10%~40%;毕扣扣灵:0~10%;盐酸巴马汀:0.01%~2%;紫堇尔明:2%~10%;夏无宁碱:15%~30%;其他生物碱及提取物:1%~5%。本发明建立了更科学高效的高纯度的夏天无总生物碱提取方法,该方法高效、简便易行,制备的夏天无总生物碱精制物的HPLC纯度大于98%,能更安全有效的发挥夏天无总生物碱的药理药效。The invention discloses refined summer free total alkaloids, a preparation method, a pharmaceutical composition and applications. The present invention provides a summer-free refined product of total alkaloids, the percentages by weight of each component in the refined product of total alkaloids are as follows: original opioid: 15% to 40%; tetrahydropalmatine: 10% to 40%; Ling: 0-10%; Palmatine Hydrochloride: 0.01%-2%; Corydalis Ermin: 2%-10%; Chardonine: 15%-30%; Other alkaloids and extracts: 1%-5% %. The present invention establishes a more scientific and efficient high-purity summer-free total alkaloid extraction method, which is efficient, simple and easy to implement, and the HPLC purity of the prepared summer-free total alkaloid refined product is greater than 98%, which can play summer more safely and effectively No pharmacological effects of total alkaloids.
Description
技术领域technical field
本发明涉及夏天无总生物碱精制物、制备方法、药物组合物及应用。The present invention relates to summer free total alkaloid refined product, preparation method, pharmaceutical composition and application.
背景技术Background technique
夏天无是罂粟科紫堇属植物伏生紫堇Corydalisdecumbens(Thunb.)Pers.的干燥块茎或全草,是我国常用中草药,具活血、通络、行气、止痛等功效。主治高血压、脑血管引起的中风偏瘫,并对风湿性关节炎、坐骨神经痛、小儿麻痹后遗症等有较好的作用。其主要有效成分为异喹啉类总生物碱。文献资料显示从夏天无中已分离得到30多个异喹啉类生物碱,主要含原阿片碱(protopine)、延胡索乙素(tetrahydropalmatine)、毕扣扣灵(bicuculline)、巴马汀(palmatine)、药根碱等生物碱。Summer Wu is the dried tuber or whole plant of Corydalis decumbens (Thunb.) Pers., a plant of the genus Corydalis of the family Papaveraceae. It is mainly used for the treatment of stroke and hemiplegia caused by high blood pressure and cerebrovascular disease, and has a good effect on rheumatoid arthritis, sciatica, and sequelae of polio. Its main active ingredients are total alkaloids of isoquinolines. Literature data show that more than 30 isoquinoline alkaloids have been isolated from Xia Wu, mainly containing protopine, tetrahydropalmatine, bicuculline, and palmatine , jatrorrhizine and other alkaloids.
目前,夏天无总碱常用的提取和精制方法有水提醇沉、渗漉、醇提、酸碱法。随着现代制剂技术的应用,大孔吸附树脂、超声、超滤膜分离、超临界CO2萃取等方法也逐渐应用于夏天无总碱的提取和精制。马宏达等研究了超临界CO2萃取法提取夏天无中总生物碱的工艺条件。以萃取压力、萃取温度和萃取时间为考察因素,以夏天无总生物碱、原阿片碱、延胡索乙素含量的综合评分及干膏率为评价指标,采用正交试验优选最佳工艺条件。结果:最佳工艺条件为萃取压力30MPa,萃取温度55℃,萃取时间2.5h。提取物中总生物碱含量约为67%,原阿片碱含量约为17%,延胡索乙素含量约为10%。(马宏达,安晔,郭涛等。超临界CO2萃取法提取夏天无总生物碱工艺研究[J].中国药房,2010,21(47):4456-4458)朱才庆等采用截留相对分子质量为6×103~1.0×104的超滤膜制备的夏天无注射液澄清、色泽好,显示出更强的药效作用。朱才庆,余华,范其坤,等.超滤膜纯化夏天无总碱的研究.中草药,2005,36(9):1319-1325.At present, the commonly used extraction and refining methods of summer non-alkali include water extraction and alcohol precipitation, percolation, alcohol extraction, and acid-base method. With the application of modern preparation technology, methods such as macroporous adsorption resin, ultrasound, ultrafiltration membrane separation, and supercritical CO2 extraction are gradually applied to the extraction and refining of summer free total alkali. Mahonda et al. studied the process conditions for extracting total alkaloids in summer mushrooms by supercritical CO 2 extraction. Taking extraction pressure, extraction temperature and extraction time as the investigation factors, taking the comprehensive score of total alkaloids, proto-opioid, and tetrahydropalmatine content in summer and the evaluation index of dry cream rate, the optimal process conditions were optimized by orthogonal experiments. Results: The optimal process conditions were extraction pressure 30MPa, extraction temperature 55℃, extraction time 2.5h. The total alkaloid content in the extract is about 67%, the original opioid content is about 17%, and the tetrahydropalmatine content is about 10%. (Ma Hongda, An Ye, Guo Tao, etc. Research on the process of extracting total alkaloids in summer by supercritical CO 2 extraction method [J]. ×103~1.0×104 ultrafiltration membrane prepared summer without injection clear, good color, showing stronger efficacy. Zhu Caiqing, Yu Hua, Fan Qikun, et al. Purification of summer free total alkaloids by ultrafiltration membrane. Chinese Herbal Medicine, 2005, 36(9):1319-1325.
CN101058576发明公开了一种夏天无总生物碱提取物及其制备方法,其制备方法是以夏天无为原料,利用超临界CO2流体萃取条件进行提取,收集萃取物,干燥得夏天无总碱提取物。应用本法提取的夏天无总生物碱平均含量采用UV法测定为90%,其中总生物碱主要包括原阿片碱、延胡索乙素、毕扣扣灵、盐酸巴马汀、紫堇尔明、夏无宁碱及其他生物碱,六个主碱的含量占提取物的75%~90%。CN101058576 invention discloses a summer free total alkaloid extract and its preparation method, its preparation method is to use summer free as raw material, utilize supercritical CO2 fluid extraction condition to extract, collect extract, dry to obtain summer free total alkaloid extract . The average content of summer free total alkaloids extracted by this method is 90% as determined by UV method, wherein the total alkaloids mainly include protopine, corydalidin, bicorkolin, palmatine hydrochloride, corydalis urmin, summer Without nicotine and other alkaloids, the content of the six main alkaloids accounts for 75% to 90% of the extract.
CN101623332中本发明公开了一种夏天无总生物碱酸盐冻干物的制备方法,以夏天无超临界CO2总生物碱提取物为原材料,加酸水溶液使其溶解,得夏天无总生物碱的酸水溶液;滤过或离心后滤过,将澄清溶液冷冻干燥,即得夏天无总生物碱酸盐冻干物。In CN101623332, the present invention discloses a preparation method of summer free total alkaloid acid salt freeze-dried product, using summer free supercritical CO2 total alkaloid extract as raw material, adding acid aqueous solution to dissolve it, and obtaining summer free total alkaloid acid aqueous solution; after filtration or centrifugation, the clarified solution is freeze-dried to obtain the freeze-dried product without total alkaloid salts in summer.
上述两个专利均提供了一种制备夏天无总生物碱的方法,但是都有不足之处。CN101058576仅提供了夏天无超临界提取夏天无总生物的方法,制备所得提取物含有油脂类成分,难于干燥,阻碍了其后续的开发应用,且对萃取时间和CO2流速进行了限制,难以应用到工业化生产。Both of the above-mentioned patents provide a method for preparing summer free total alkaloids, but both have disadvantages. CN101058576 only provides the method of no supercritical extraction in summer without total organisms in summer, and the prepared extract contains oily components, which is difficult to dry, which hinders its subsequent development and application, and the extraction time and CO The flow rate is limited, so it is difficult to apply to industrial production.
CN101623332B专利在CN101058576B基础上以夏天无超临界提取的夏天无总生物碱粗提物为原料通过酸溶液处理后冷冻干燥制备总生物碱酸盐冻干物的方法,制备所得的冻干物总生物碱的含量在80%以上。该专利对夏天无总生物碱的富集、纯化没有做更进一步的研究,制得的夏天无提取物纯度不够高,限制了夏天无总生物碱的应用范围。CN101623332B patent is based on CN101058576B the method of preparing the total alkaloid salt lyophilizate by using the summer non-supercritical extraction summer non-total alkaloid crude extract as raw material through acid solution treatment and freeze-drying to prepare the total alkaloid salt freeze-dried product. The content of alkali is more than 80%. This patent does not conduct further research on the enrichment and purification of the total summer alkaloids, and the purity of the prepared summer non-alcoholic extract is not high enough, which limits the application range of the total summer non-alkaloids.
夏天无总生物碱制剂临床主要用于治疗老年痴呆,脑梗死,中小学生假性近视等,有很大的市场前景,但是目前的夏天无总生物碱的提取分离技术多采用酸提过树脂柱法,工艺繁杂,耗时长,得到的总生物碱的纯度不高的缺点。因此,寻找工艺简单、提取率高、提取到的夏天无总生物碱的纯度好、适合于大规模工业化生产的提取方法是目前急需解决的技术难题。Summer-free total alkaloid preparations are mainly used to treat senile dementia, cerebral infarction, pseudomyopia of primary and middle school students, etc., and have great market prospects, but the current extraction and separation technology of summer-free total alkaloids mostly uses acid extraction through resin columns method, the process is complicated, it takes a long time, and the purity of the total alkaloids obtained is not high. Therefore, it is an urgent technical problem to find an extraction method with simple process, high extraction rate, good purity of the extracted summer free of total alkaloids, and suitable for large-scale industrial production.
发明内容Contents of the invention
本发明要解决的技术问题是为了克服现有夏天无总生物碱提取方法步骤繁琐、提取率低、提取得到的提取物纯度低,杂质含量高,不适合药用、不适合于工业化生产等缺陷,而提供了一种夏天无总生物碱精制物、制备方法、药物组合物及应用。本发明建立了更科学高效的高纯度的夏天无总生物碱提取方法,该方法高效、简便易行,制备的夏天无总生物碱的HPLC纯度大于98%,能更安全有效的发挥夏天无总生物碱的药理药效。The technical problem to be solved by the present invention is to overcome the defects of the existing summer-free total alkaloid extraction method, such as cumbersome steps, low extraction rate, low purity of the extracted extract, high impurity content, unsuitable for medicinal use, and unsuitable for industrial production. , and provide a summer free total alkaloid refined product, preparation method, pharmaceutical composition and application. The present invention establishes a more scientific and efficient high-purity extraction method of summer free total alkaloids. Pharmacological effects of alkaloids.
本发明提供了一种夏天无总生物碱精制物,其中,总生物碱精制物中各组分的重量百分比分别为:原阿片碱:15%~40%;延胡索乙素:10%~40%;毕扣扣灵:0~10%(不包括0);盐酸巴马汀:0.01%~2%;紫堇尔明:2%~10%;夏无宁碱:15%~30%;其他生物碱及提取物:1%~5%。The present invention provides a refined product without total alkaloids in summer, wherein the percentages by weight of each component in the refined product of total alkaloids are: protopine: 15%-40%; tetrahydropalmatine: 10%-40% ; Bikoukouling: 0-10% (excluding 0); Palmatine hydrochloride: 0.01%-2%; Corydalis Ermin: 2%-10%; Chardonine: 15%-30%; other biological Alkali and extract: 1% to 5%.
本发明中,所述的夏天无总生物碱精制物,采用HPLC法测定,总生物碱含量为60%~100%,其中,六个主碱总含量占夏天无总生物碱精制物的95%以上。In the present invention, the refined summer free total alkaloids are measured by HPLC method, and the total alkaloid content is 60% to 100%, wherein the total content of the six main alkaloids accounts for 95% of the summer free total alkaloid refined products above.
本发明还提供了所述的夏天无总生物碱精制物的制备方法,其包括以下步骤:The present invention also provides the preparation method of the summer free total alkaloid refined product, which comprises the following steps:
步骤1:以夏天无(罂粟科植物伏生紫堇)的块茎、粉碎、碱化,得到碱化后的夏天无;所述的碱化中,所述的碱与所述的夏天无的质量比值为0.001~1,优选0.001~0.1。Step 1: use the tuber of summer fruit (Papaveraceae plant Viola corydalis), pulverize and alkalize to obtain alkalized summer fruit; in the alkalization, the quality of the alkali and the described summer fruit The ratio is 0.001-1, preferably 0.001-0.1.
步骤2:将步骤1得到的碱化后的夏天无,在超临界CO2萃取和膜分离相耦合的萃取仪中进行萃取和分离,干燥,得到夏天无总生物碱精制物。Step 2: Extract and separate the alkalized summer free obtained in step 1 in an extractor coupled with supercritical CO2 extraction and membrane separation, and dry to obtain refined summer free total alkaloids.
步骤1中,所述的粉碎,优选粉碎至夏天无(罂粟科植物伏生紫堇)的粒径为10目~60目(即1.74mm~0.273mm)。所述的碱化,优选采用无机碱进行碱化,所述的无机碱优选氨水溶液、氢氧化钙、碳酸钠和碳酸氢钠中的一种或多种,进一步优选氨水溶液,所述的氨水溶液的质量浓度优选1%~10%,所述的质量浓度是指氨气的质量占氨水溶液总质量的百分比。所述的氨水溶液可以采用氨水试剂与水混合得到,所述的氨水试剂与水的体积比优选5%~10%,所述的体积比是指氨水试剂的体积与水体积的百分比。所述的氨水试剂可以为本领域中常规市售氨水试剂,所述的氨水试剂的浓度优选2%~30%。所述的无机碱优选以其水溶液的形式使用,所述的无机碱的水溶液的浓度优选1%~10%,所述的浓度是指无机碱的质量占无机碱的水溶液的总质量的百分比。In step 1, the crushing is preferably crushed until the particle size of the summer grass (Papaceae plant Corydalis viticum) is 10 mesh to 60 mesh (that is, 1.74 mm to 0.273 mm). Described alkalization, preferably adopts inorganic base to carry out alkalization, and described inorganic base is preferably one or more in ammonia solution, calcium hydroxide, sodium carbonate and sodium bicarbonate, more preferably ammonia solution, described ammonia The mass concentration of the aqueous solution is preferably 1%-10%, and the mass concentration refers to the percentage of the mass of ammonia gas in the total mass of the ammonia solution. The ammonia solution can be obtained by mixing ammonia reagent with water, the volume ratio of the ammonia reagent to water is preferably 5% to 10%, and the volume ratio refers to the percentage of the volume of the ammonia reagent to the volume of water. The ammonia water reagent can be conventional commercially available ammonia water reagent in the field, and the concentration of the ammonia water reagent is preferably 2%-30%. The inorganic base is preferably used in the form of its aqueous solution, and the concentration of the aqueous solution of the inorganic base is preferably 1% to 10%, and the concentration refers to the percentage of the mass of the inorganic base in the total mass of the aqueous solution of the inorganic base.
步骤2中,所述的超临界CO2萃取和分离的时间优选0.5~5h;所述的超临界CO2萃取和分离时采用的夹带剂优选甲醇和/或乙醇,进一步优选乙醇,所述的乙醇优选质量百分比为95%的乙醇水溶液,所述的质量百分比是指乙醇的质量占乙醇水溶液总质量的百分比。所述的“超临界CO2萃取和膜分离相耦合的萃取仪”中的膜优选超滤膜、纳滤膜、反渗透膜或中空纤维膜,进一步优选纳滤膜;所述的纳滤膜的孔径优选1纳米~3纳米。所述的超滤膜的孔径优选纳米10纳米~40纳米。所述的反渗透膜的孔径优选1纳米~5纳米。所述的中空纤维膜的孔径优选1纳米~40纳米。In step 2, the time for the extraction and separation of the supercritical CO2 is preferably 0.5 to 5h; the entrainer used during the extraction and separation of the supercritical CO2 is preferably methanol and/or ethanol, more preferably ethanol, and the Ethanol is preferably an aqueous ethanol solution with a mass percentage of 95%, and the mass percentage refers to the percentage of the mass of ethanol in the total mass of the aqueous ethanol solution. The membrane in the "supercritical CO extraction and membrane separation coupled extractor" is preferably an ultrafiltration membrane, a nanofiltration membrane, a reverse osmosis membrane or a hollow fiber membrane, more preferably a nanofiltration membrane; the nanofiltration membrane The pore size is preferably 1 nm to 3 nm. The pore size of the ultrafiltration membrane is preferably 10 nm to 40 nm. The pore size of the reverse osmosis membrane is preferably 1 nm to 5 nm. The pore diameter of the hollow fiber membrane is preferably 1 nm to 40 nm.
步骤2中,所述的超临界CO2萃取和膜分离相耦合的萃取仪根据《中药提取分离新技术》一书(2010年4月,化学工业出版社出版,P353页)中记载的原理图进行组装,所述的超临界CO2萃取和膜分离相耦合的萃取仪包括以下部件:萃取装置、分离装置、高压泵、膜装置、冷却器和气体储罐。In step 2 , described supercritical CO Extraction and the extractor of membrane separation phase coupling are according to the schematic diagram recorded in the book "New Technology for Extraction and Separation of Chinese Medicine" (April 2010, published by Chemical Industry Press, page P353) Assembled, the extraction apparatus coupled with supercritical CO 2 extraction and membrane separation includes the following components: extraction device, separation device, high-pressure pump, membrane device, cooler and gas storage tank.
本发明中,所述的夏天无总生物碱精制物的制备方法优选还包括步骤3,进一步优选还包括步骤3和步骤4,再进一步优选还包括步骤3、步骤4和步骤5。In the present invention, the method for preparing the refined summer free total alkaloids preferably further includes step 3, more preferably further includes step 3 and step 4, and still more preferably further includes step 3, step 4 and step 5.
步骤3:将步骤2得到的夏天无总生物碱精制物调节pH至2~5,采用超声波萃取,然后采用超滤或微滤膜过滤,得到纯化后的夏天无总生物碱精制物的溶液。Step 3: adjust the pH of the refined summer free total alkaloids obtained in step 2 to 2-5, extract by ultrasonic wave, and then filter by ultrafiltration or microfiltration membrane to obtain the purified summer free total alkaloid refined solution.
步骤4:将步骤3得到的夏天无总生物碱精制物的溶液调节pH为8~12,过滤,固相用水洗至中性,得到进一步纯化后的夏天无总生物碱精制物;Step 4: adjusting the pH of the refined summer free total alkaloid solution obtained in step 3 to 8-12, filtering, washing the solid phase with water until neutral, and obtaining further purified summer free total alkaloid refined product;
步骤5:将步骤4得到的进一步纯化后的夏天无总生物碱精制物重结晶,得到重结晶后的夏天无总生物碱精制物。Step 5: Recrystallize the further purified refined product of summer without total alkaloids obtained in step 4 to obtain the refined product of summer without total alkaloids after recrystallization.
步骤3中,所述的超声波萃取的频率优选30Hz~80Hz,所述的超声波萃取的时间优选0.5小时~3小时。所述的超滤或微滤膜的孔径优选0.3微米~0.8微米;所述的调节pH优选用酸进行调节,所述的酸优选无机酸和/或有机酸,所述的无机酸优选盐酸,所述的有机酸优选酒石酸。所述的酸优选以其水溶液的形式使用,当所述的酸以其水溶液的形式使用时,所述的酸的水溶液的质量百分浓度优选1%~10%,进一步优选1%~5%,所述的质量百分比是指酸的质量占酸的水溶液总质量的百分比。所述的酸的水溶液与所述的步骤2得到的夏天无总生物碱的精制物的体积比值优选5~10,进一步优选5~8。步骤3优选包括干燥的步骤,将所述的纯化后的夏天无总生物碱精制物的溶液干燥得到纯化后的夏天无总生物碱精制物;所述的干燥可以按照本领域中该类操作的常规方法和条件。In step 3, the frequency of the ultrasonic extraction is preferably 30 Hz to 80 Hz, and the time of the ultrasonic extraction is preferably 0.5 hours to 3 hours. The pore size of the ultrafiltration or microfiltration membrane is preferably 0.3 micron to 0.8 micron; the pH adjustment is preferably adjusted with an acid, and the acid is preferably an inorganic acid and/or an organic acid, and the inorganic acid is preferably hydrochloric acid. Described organic acid is preferably tartaric acid. The acid is preferably used in the form of its aqueous solution. When the acid is used in the form of its aqueous solution, the mass percent concentration of the acid aqueous solution is preferably 1% to 10%, more preferably 1% to 5%. , the mass percentage refers to the percentage of the mass of the acid in the total mass of the aqueous acid solution. The volume ratio of the aqueous acid solution to the total alkaloid-free refined product obtained in step 2 is preferably 5-10, more preferably 5-8. Step 3 preferably includes a drying step, drying the solution of the purified summer summer without total alkaloids refined product to obtain the purified summer summer without total alkaloids refined product; the drying can be performed according to this type of operation in the art Conventional Methods and Conditions.
步骤4中,所述的pH优选为9~11。所述的调节pH优选采用无机碱进行调节,所述的无机碱优选氢氧化钠或氢氧化钾,所述的无机碱可以以其水溶液的形式使用,当所述的无机碱以其水溶液的形式使用时,所述的无机碱的水溶液的质量浓度优选3%~15%,进一步优选4%~10%,所述的质量浓度是指无机碱的质量占无机碱水溶液总质量的百分比。步骤4优选包括干燥的步骤,所述的干燥可以按照本领域中该类操作的常规方法和条件。In step 4, the pH is preferably 9-11. The pH adjustment is preferably adjusted with an inorganic base, preferably sodium hydroxide or potassium hydroxide, the inorganic base can be used in the form of its aqueous solution, when the inorganic base is in the form of its aqueous solution When used, the mass concentration of the aqueous solution of the inorganic base is preferably 3% to 15%, more preferably 4% to 10%. The mass concentration refers to the percentage of the mass of the inorganic base to the total mass of the aqueous solution of the inorganic base. Step 4 preferably includes a drying step, and the drying can be performed according to conventional methods and conditions of this type of operation in the art.
步骤5中,所述的重结晶可以采用本领域中该类操作的常规方法和条件。所述的重结晶采用的溶剂优选醇类溶剂和/或卤代烃类溶剂,所述的醇类溶剂优选甲醇和/或乙醇,所述的卤代烃类溶剂优选氯代烃类溶剂,所述的氯代烃类溶剂优选氯仿。步骤5优选包括干燥的步骤,所述的干燥可以按照本领域中该类操作的常规方法和条件。In step 5, the recrystallization can adopt conventional methods and conditions of this type of operation in the art. The solvent used for the recrystallization is preferably an alcohol solvent and/or a halogenated hydrocarbon solvent, the preferred methanol and/or ethanol of the alcohol solvent, and the preferred chlorinated hydrocarbon solvent of the halogenated hydrocarbon solvent, so The above-mentioned chlorinated hydrocarbon solvent is preferably chloroform. Step 5 preferably includes a drying step, and the drying can be performed according to conventional methods and conditions for this type of operation in the art.
本发明还提供了所述的夏天无总生物碱的精制物在制备治疗和/或预防脑缺血或再灌注造成的神经元细胞损伤的疾病的药物中的应用。The present invention also provides the application of the refined product of summer free of total alkaloids in the preparation of medicines for treating and/or preventing neuron cell damage caused by cerebral ischemia or reperfusion.
本发明还提供了一种药物组合物,其含有治疗有效量的所述的夏天无总生物碱的精制物和药学上可接受的载体。本发明中,所述的治疗有效量优选质量百分比为0.1%~99.9%,所述的质量百分比是指所述的夏天无总生物碱的精制物占药物组合物总质量的百分比。所述的药学上可接受的载体为本领域中常规的药学上可接受的载体。The present invention also provides a pharmaceutical composition, which contains a therapeutically effective amount of the refined summer summer free of total alkaloids and a pharmaceutically acceptable carrier. In the present invention, the therapeutically effective amount is preferably 0.1%-99.9% by mass, and the mass percentage refers to the percentage of the total alkaloid-free refined product of summer in the total mass of the pharmaceutical composition. The pharmaceutically acceptable carrier is a conventional pharmaceutically acceptable carrier in the art.
本发明还提供了所述的药物组合物在制备治疗和/或预防脑缺血或再灌注造成的神经元细胞损伤的疾病的药物中的应用。The present invention also provides the application of the pharmaceutical composition in the preparation of medicines for treating and/or preventing neuronal cell damage caused by cerebral ischemia or reperfusion.
本发明中,所述的脑缺血或再灌注造成的神经元细胞损伤的疾病包括脑血栓和脑卒中。In the present invention, the diseases of neuron cell injury caused by cerebral ischemia or reperfusion include cerebral thrombosis and cerebral apoplexy.
在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。On the basis of not violating common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain preferred examples of the present invention.
本发明所用试剂和原料均市售可得。The reagents and raw materials used in the present invention are all commercially available.
本发明的积极进步效果在于:本发明建立了更科学高效的高纯度的夏天无总生物碱的提取方法,该方法高效、简便易行,制备的夏天无总生物碱精制物的HPLC纯度大于98%,能更安全有效的发挥夏天无总生物碱的药理药效。The positive progress effect of the present invention is: the present invention has established a more scientific and efficient high-purity extraction method of summer free total alkaloids, the method is efficient, simple and easy to implement, and the HPLC purity of the prepared summer free total alkaloids is greater than 98 %, it can more safely and effectively exert the pharmacological effects of no total alkaloids in summer.
附图说明Description of drawings
图1为CO2超临界萃取和膜分离相耦合的萃取过程的示意图。Figure 1 is a schematic diagram of the CO2 extraction process coupled with supercritical extraction and membrane separation.
具体实施方式detailed description
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。The present invention is further illustrated below by means of examples, but the present invention is not limited to the scope of the examples. For the experimental methods that do not specify specific conditions in the following examples, select according to conventional methods and conditions, or according to the product instructions.
下列实施例中采用的超临界CO2萃取和膜耦合的萃取仪按照图1所示的示意图进行装配。The supercritical CO2 extraction and membrane-coupled extraction apparatus used in the following examples were assembled according to the schematic diagram shown in Figure 1.
实施例1:夏天无总生物碱精制物的制备Embodiment 1: Preparation of total alkaloid-free refined product in summer
取夏天无的干燥块茎,粉碎,得到粒度为10目~40目的药材粉末;取药材粉末300g,加入体积比为6%氨水作为碱化剂(所述的体积比是指氨水试剂的体积占氨水溶液总体积的百分比,氨水试剂的质量浓度为25%~28%,所述的质量浓度是指氨气的质量占氨水试剂总质量的百分比),用量为夏天无药材重量的50%,浸润2h;将药材投入超临界CO2萃取和膜耦合(孔径为0.8微米的超滤膜)的萃取仪中,以甲醇为夹带剂,萃取30分钟后,停止萃取,得到总生物碱提取物,干燥,即得。高效液相色谱法测定总生物碱含量为98.47%。经HPLC测定,其重量百分比组成包括:原阿片碱:34.89%,延胡索乙素:24.56%,毕扣扣灵:3.51%,盐酸巴马汀:1.84%,夏无宁碱:19.77%,紫堇尔明:9.58%,其他碱含量4.32%。Get the dry tuber that does not have in summer, pulverize, and obtain particle size and be 10 order ~ 40 order medicinal material powder; Get medicinal material powder 300g, add volume ratio and be 6% ammoniacal liquor as alkalizing agent (described volume ratio refers to that the volume of ammoniacal liquor reagent occupies ammonia The percentage of the total volume of the aqueous solution, the mass concentration of the ammonia reagent is 25% to 28%, the mass concentration refers to the percentage of the quality of ammonia gas in the total mass of the ammonia reagent), and the dosage is 50% of the weight of the summer non-medicinal material, soaked for 2h put medicinal material into supercritical CO2extraction and membrane coupling (aperture is the ultrafiltration membrane of 0.8 micron) in the extractor, take methanol as entrainer, after extraction 30 minutes, stop extraction, obtain total alkaloid extract, dry, Instantly. The total alkaloid content determined by high performance liquid chromatography was 98.47%. As determined by HPLC, its composition in weight percent includes: proto-opiate: 34.89%, tetrahydropalmatine: 24.56%, bikkoling: 3.51%, palmatine hydrochloride: 1.84%, chardonine: 19.77%, Corydalis Ming: 9.58%, other alkali content 4.32%.
实施例2:夏天无总生物碱精制物的制备Embodiment 2: Preparation of total alkaloid-free refined product in summer
取夏天无的干燥块茎,粉碎,得到粒度为20目~40目的药材粉末;取药材粉末300g,加入体积比为10%氨水作为碱化剂(所述的体积比是指氨水试剂的体积占氨水溶液总体积的百分比,氨水试剂的质量浓度为25%~28%,所述的质量浓度是指氨气的质量占氨水试剂总质量的百分比),用量为夏天无药材重量的60%,浸润1h;将药材投入超临界CO2萃取和膜耦合(采用孔径为2纳米的纳滤膜)的萃取仪中,以质量百分比为95%乙醇为夹带剂(所述的质量百分比是指乙醇的质量占乙醇水溶液总质量的百分比),萃取时间1.5h,高效液相色谱法测定总生物碱含量为98.95%。经HPLC测定,其重量百分比组成包括:原阿片碱:30.52%,延胡索乙素:28.93%,毕扣扣灵:0.01%,盐酸巴马汀:0.09%,夏无宁碱:25.64%,紫堇尔明:9.73%,其他碱含量4.03%。Get the dry tuber that does not have in summer, pulverize, and obtain the medicinal material powder that particle size is 20 order~40 order; Get medicinal material powder 300g, add volume ratio and be 10% ammoniacal liquor as alkalizing agent (described volume ratio refers to that the volume of ammoniacal liquor reagent occupies ammonia The percentage of the total volume of the aqueous solution, the mass concentration of the ammonia water reagent is 25% to 28%, and the mass concentration refers to the percentage of the quality of ammonia gas in the total mass of the ammonia water reagent), and the dosage is 60% of the weight of the summer non-medicinal material, soaked for 1h Medical material is dropped into supercritical CO Extraction and membrane coupling (adopting aperture is the nanofiltration membrane of 2 nanometers) in the extractor, be 95% ethanol as entrainer with mass percent (described mass percent refers to the mass percent of ethanol accounts for The percentage of the total mass of ethanol aqueous solution), the extraction time is 1.5h, and the total alkaloid content determined by high performance liquid chromatography is 98.95%. As determined by HPLC, its composition by weight percentage includes: proto-opiate: 30.52%, tetrahydropalmatine: 28.93%, bikkoling: 0.01%, palmatine hydrochloride: 0.09%, chardonine: 25.64%, and Corydalis Ming: 9.73%, other alkali content 4.03%.
实施例3:夏天无总生物碱精制物的制备方法Embodiment 3: the preparation method of total alkaloid-free refined product in summer
取夏天无的干燥块茎,打粉,得到粒度为10目~20目的药材粉末;取药材粉末200g,加入体积比为7%氨水溶液作为碱化剂(所述的体积比是指氨水试剂的体积占氨水溶液总体积的百分比,氨水试剂的质量浓度为25%~28%,所述的质量浓度是指氨气的质量占氨水试剂总质量的百分比),用量为夏天无药材重量的50%,浸润3h;将药材投入超临界CO2萃取和膜耦合(采用孔径为0.1微米的中空纤维膜)的萃取仪中,以质量百分比为95%乙醇为夹带剂(所述的质量百分比是指乙醇的质量占乙醇水溶液总质量的百分比),萃取时间40分钟,得到的总生物碱用质量百分比为1%盐酸水溶液300mL(所述的质量百分比是指氯化氢的质量占盐酸水溶液总质量的百分比),超声(超声频率为80HZ)萃取2h,1.0μm滤膜滤过,加入质量百分比为8%氢氧化钾溶液调pH10~11(所述的质量百分比是指氢氧化钾的质量占氢氧化钾总质量的百分比),过滤得沉淀,高效液相色谱法测定总生物碱含量为98.88%。经HPLC测定,其重量百分比组成包括:原阿片碱:35.68%,延胡索乙素:19.36%,毕扣扣灵:4.64%,盐酸巴马汀:0.61%,夏无宁碱:28.71%,紫堇尔明:8.75%,其他碱含量1.13%。Get the dry tuber that does not have in summer, make powder, and obtain particle size and be 10 order ~ 20 order medicinal material powder; Get medicinal material powder 200g, add volume ratio and be 7% ammoniacal solution as alkalizing agent (the volume ratio refers to the volume of ammonia water reagent accounts for The percentage of total volume of ammonia solution, the mass concentration of ammonia reagent is 25%~28%, described mass concentration refers to the percentage of the quality of ammonia gas accounting for the total mass of ammonia reagent), and the consumption is 50% of the summer non-medicinal weight, infiltrating 3h; the medicinal material is put into supercritical CO2 extraction and membrane coupling (using a hollow fiber membrane with a pore size of 0.1 micron) in the extractor, with a mass percentage of 95% ethanol as an entrainer (the mass percentage refers to the quality of ethanol Accounting for the percentage of the total mass of ethanol aqueous solution), the extraction time was 40 minutes, and the mass percentage of the total alkaloid obtained was 1% hydrochloric acid aqueous solution 300mL (the described mass percentage refers to the quality of hydrogen chloride accounts for the percentage of the total mass of hydrochloric acid aqueous solution), ultrasonic ( Ultrasonic frequency is 80H Z ) extraction 2h, 1.0 μm filter membrane filtration, add mass percentage and be 8% potassium hydroxide solution and adjust pH10~11 (the described mass percentage refers to the quality of potassium hydroxide accounts for the total mass of potassium hydroxide percentage), filtered to obtain a precipitate, and the high-performance liquid chromatography determined that the total alkaloid content was 98.88%. As determined by HPLC, its composition by weight percentage includes: proto-opiate: 35.68%, tetrahydropalmatine: 19.36%, bicorkolin: 4.64%, palmatine hydrochloride: 0.61%, chardonine: 28.71%, Corydalis Ming: 8.75%, other alkali content 1.13%.
实施例4:夏天无总生物碱精制物的制备方法Embodiment 4: the preparation method of total alkaloid-free refined product in summer
取夏天无的干燥块茎,打粉,得到粒度为20目~40目的夏天无药材粉末;取夏天无药材粉末300g,加入体积比10%氨水作为碱化剂(所述的体积比是指氨水试剂的体积占氨水溶液总体积的百分比,氨水试剂的质量浓度为25%~28%,所述的质量浓度是指氨气的质量占氨水试剂总质量的百分比),用量为夏天无药材重量的50%,浸润2.5h;将药材投入超临界CO2萃取和膜耦合(采用孔径为1纳米的复合纳滤膜)的萃取仪中,以质量百分比为95%乙醇为夹带剂(所述的质量百分比是指乙醇的质量占乙醇水溶液总质量的百分比),萃取1小时后,即得。用质量百分比为1%盐酸水溶液500ml,超声(超声频率60HZ)萃取1h,0.45μm滤膜滤过,加入质量百分比为10%氢氧化钠溶液调pH9~10(所述的质量百分比是指氢氧化钾的质量占氢氧化钾总质量的百分比),过滤得沉淀,高效液相色谱法测定总生物碱含量为98.68%。经HPLC测定,其重量百分比组成包括:原阿片碱:20.68%,延胡索乙素:32.16%,毕扣扣灵:8.84%,盐酸巴马汀:0.50%,夏无宁碱:28.71%,紫堇尔明:6.75%,其他碱1.04%。Get the dry tuber of summer without, powder, and obtain particle size and be 20 mesh~40 mesh without summer medicinal material powder; Get summer without medicinal material powder 300g, add volume ratio 10% ammoniacal liquor as alkalizing agent (described volume ratio refers to the ammoniacal liquor reagent Volume accounts for the percentage of the total volume of ammonia solution, the mass concentration of ammonia water reagent is 25%~28%, described mass concentration refers to the percentage of the quality of ammonia gas accounting for the total mass of ammonia water reagent), and consumption is 50% of the summer non-medicinal material weight , infiltrate 2.5h; Medical material is dropped into supercritical CO Extraction and membrane coupling (adopting aperture is the composite nanofiltration membrane of 1 nanometer) in the extractor, be 95% ethanol as entrainer with mass percent (the described mass percent is Refers to the mass of ethanol as a percentage of the total mass of the aqueous ethanol solution), which is obtained after 1 hour of extraction. 500ml of 1% hydrochloric acid aqueous solution by mass percentage, ultrasonic (ultrasonic frequency 60H Z ) extraction for 1h, 0.45 μm filter membrane filtration, adding mass percentage of 10% sodium hydroxide solution to adjust pH9~10 (the mass percentage refers to hydrogen The mass of potassium oxide accounts for the percentage of the total mass of potassium hydroxide), and the precipitate is obtained by filtration, and the total alkaloid content determined by high performance liquid chromatography is 98.68%. As determined by HPLC, its composition by weight percentage includes: proto-opiate: 20.68%, tetrahydropalmatine: 32.16%, bicorkolin: 8.84%, palmatine hydrochloride: 0.50%, chardonine: 28.71%, and Corydalis Ming: 6.75%, other bases 1.04%.
实施例5:夏天无总生物碱精制物的制备方法Embodiment 5: the preparation method of total alkaloid-free refined product in summer
取夏天无的干燥块茎,打粉,得到粒度为30目~40目的夏天无药材粉末;取夏天无药材粉末8000g,加入体积比为10%氨水作为碱化剂(所述的体积比是指氨水试剂的体积占氨水溶液总体积的百分比,氨水试剂的质量浓度为25%~28%,所述的质量浓度是指氨气的质量占氨水试剂总质量的百分比),用量为夏天无药材重量的70%,浸润24h;将药材投入超临界CO2萃取和膜耦合(采用孔径为15纳米反渗透膜)的萃取仪中,以质量百分比为95%乙醇为夹带剂(所述的质量百分比是指乙醇的质量占乙醇水溶液总质量的百分比),萃取时间1h,干燥,即得。再用质量百分比为2%盐酸水溶液300mL(所述的质量百分比是指氯化氢的质量占盐酸水溶液总质量的百分比),超声(超声频率80HZ)萃取0.5h,孔径为0.1微米的滤膜滤过,加入质量百分比为10%氢氧化钠溶液调pH9~10(所述的质量百分比是指氢氧化钠的质量占氢氧化钠总质量的百分比),过滤得沉淀,用甲醇重结晶,高效液相色谱法测定总生物碱含量为99.88%。经HPLC测定,其重量百分比组成包括:原阿片碱:29.28%,延胡索乙素:23.83%,毕扣扣灵:8.52%,盐酸巴马汀:1.90%,夏无宁碱:29.71%,紫堇尔明:4.62%,其他碱2.02%。Get the dry tuber of summer without, powder, and obtain particle size and be that 30 order~40 order summer without medicinal material powder; Get summer without medicinal material powder 8000g, add volume ratio and be 10% ammoniacal liquor as alkalizing agent (described volume ratio refers to ammoniacal liquor reagent The volume accounts for the percentage of total volume of ammonia solution, and the mass concentration of ammonia water reagent is 25%~28%, and described mass concentration refers to the percentage that the quality of ammonia gas accounts for the total mass of ammonia water reagent), and consumption is 70% of the summer non-medicinal material weight %, infiltrate 24h; Medical material is dropped into supercritical CO Extraction and membrane coupling (adopting aperture is 15 nanometer reverse osmosis membrane) in the extractor, be 95% ethanol with mass percentage as entrainer (described mass percentage refers to ethanol The mass of the ethanol solution accounts for the percentage of the total mass of the ethanol aqueous solution), the extraction time is 1 h, and it is dried to obtain. Then use mass percent as 2% hydrochloric acid aqueous solution 300mL (the described mass percent refers to the percentage that the quality of hydrogen chloride accounts for the total mass of hydrochloric acid aqueous solution), ultrasonic (ultrasonic frequency 80H Z ) extraction 0.5h, aperture is the filter membrane filtration of 0.1 micron , add mass percentage and be 10% sodium hydroxide solution and adjust pH9~10 (the described mass percentage refers to the percentage that the quality of sodium hydroxide accounts for the total mass of sodium hydroxide), filters to obtain precipitation, recrystallizes with methanol, high-efficiency liquid phase The total alkaloid content determined by chromatography is 99.88%. As determined by HPLC, its composition by weight percentage includes: proto-opiate: 29.28%, tetrahydropalmatine: 23.83%, bicorkolin: 8.52%, palmatine hydrochloride: 1.90%, chardonine: 29.71%, and Corydalis Ming: 4.62%, other bases 2.02%.
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410380316.8A CN105311119A (en) | 2014-08-04 | 2014-08-04 | Refined rhizoma corydalis decumbentis total alkaloid product, preparation method thereof, pharmaceutical composition and application of refined rhizoma corydalis decumbentis total alkaloid product and pharmaceutical composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410380316.8A CN105311119A (en) | 2014-08-04 | 2014-08-04 | Refined rhizoma corydalis decumbentis total alkaloid product, preparation method thereof, pharmaceutical composition and application of refined rhizoma corydalis decumbentis total alkaloid product and pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105311119A true CN105311119A (en) | 2016-02-10 |
Family
ID=55240076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410380316.8A Pending CN105311119A (en) | 2014-08-04 | 2014-08-04 | Refined rhizoma corydalis decumbentis total alkaloid product, preparation method thereof, pharmaceutical composition and application of refined rhizoma corydalis decumbentis total alkaloid product and pharmaceutical composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105311119A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107176960A (en) * | 2016-03-10 | 2017-09-19 | 江苏康缘药业股份有限公司 | A kind of alkaloid compound and its preparation and application |
CN110141605A (en) * | 2019-04-19 | 2019-08-20 | 南京康齐生物科技有限公司 | A kind of preparation method of snowpoppy total alkaloid nanoparticle |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101058576A (en) * | 2006-04-21 | 2007-10-24 | 上海医药工业研究院 | Rhizoma corydalis decumbentis extract, preparation method thereof, medicament composition containing the rhizoma corydalis decumbentis and application thereof |
CN101623332A (en) * | 2008-07-10 | 2010-01-13 | 上海医药工业研究院 | Method for preparing rhizoma corydalis decumbeutis total alkaloids acid salt freeze-drying substance and application of obtained freeze-drying substance |
-
2014
- 2014-08-04 CN CN201410380316.8A patent/CN105311119A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101058576A (en) * | 2006-04-21 | 2007-10-24 | 上海医药工业研究院 | Rhizoma corydalis decumbentis extract, preparation method thereof, medicament composition containing the rhizoma corydalis decumbentis and application thereof |
CN101623332A (en) * | 2008-07-10 | 2010-01-13 | 上海医药工业研究院 | Method for preparing rhizoma corydalis decumbeutis total alkaloids acid salt freeze-drying substance and application of obtained freeze-drying substance |
Non-Patent Citations (2)
Title |
---|
胡雪勇等: "夏天无总碱抗实验性脑缺血的作用", 《中西医结合学报》 * |
郭清泉等: "超临界流体耦合技术的现状及发展", 《现代化工》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107176960A (en) * | 2016-03-10 | 2017-09-19 | 江苏康缘药业股份有限公司 | A kind of alkaloid compound and its preparation and application |
CN107176960B (en) * | 2016-03-10 | 2019-07-12 | 江苏康缘药业股份有限公司 | A kind of alkaloid compound and its preparation and application |
CN110141605A (en) * | 2019-04-19 | 2019-08-20 | 南京康齐生物科技有限公司 | A kind of preparation method of snowpoppy total alkaloid nanoparticle |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108752231B (en) | Method for extracting theanine from sweet tea and simultaneously extracting rubusoside and tea polyphenol | |
CN101838200B (en) | Method for extracting and separating chlorogenic acid from honeysuckle | |
CN101671294B (en) | Method for continuously extracting and separating 1-Deoxynojirimycin (DNJ) and flavone from mulberry leaves | |
CN102532244A (en) | Method for preparing high-purity asiaticosid | |
CN102964460A (en) | Method for continuously extracting and separating polysaccharides and 1-deoxynojirimycin from mulberry leaves | |
CN110003197A (en) | A kind of extraction process of tropane alkaloids | |
CN101906129A (en) | A method for separating and purifying saponin (glycoside) | |
CN113896754A (en) | A kind of industrialized production method of extracting and purifying baicalin from Scutellaria baicalensis | |
CN102617469A (en) | Method for extracting huperzine a from huperzia serrata | |
CN1962592A (en) | Method for separating and purifying polydatin and resveratrol from traditional Chinese medicine giant knotweed | |
CN101168537A (en) | Method for preparing andrographolide and dehydroandrographolide simultaneously | |
CN101143887B (en) | Method for separating and preparing corosolic acid from loquat leaves | |
WO2012061984A1 (en) | Method for preparing albiflorin and paeoniflorin | |
CN101288695A (en) | Preparation technology of tetrandrine alkaloid | |
CN101973985A (en) | Method for preparing mangiferin | |
CN105311119A (en) | Refined rhizoma corydalis decumbentis total alkaloid product, preparation method thereof, pharmaceutical composition and application of refined rhizoma corydalis decumbentis total alkaloid product and pharmaceutical composition | |
CN104098465A (en) | Technological method for extraction of protocatechuic acid from Blumea riparia (Bl.) DC | |
CN104418852B (en) | A kind of high-purity coptisine extracting method and application | |
CN106046848A (en) | Method for extracting and purifying anthocyanin from mulberry pomace | |
CN102399251A (en) | Method for preparing high-purity geniposide | |
CN103509034B (en) | A kind of method extracting arteannuin from fresh artemisia annua | |
CN101254360B (en) | An imprinted membrane plate and its application in crystallization and purification of substances | |
CN102908371A (en) | Method for preparing high-purity ferulic acid from angelica sinensis | |
CN102503998B (en) | Method for rapidly separating quercetin from flos albiziae | |
CN106674364A (en) | Extracting method for dendrobium polysaccharide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160210 |